Literature DB >> 15996945

The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.

Tadeusz Robak, Jerzy Z Blonski, Marek Kasznicki, Joanna Góra-Tybor, Anna Dmoszyñska, Aleksander Skotñicki.   

Abstract

We present the long-term follow-up and results of subsequent treatments in patients with chronic lymphocytic leukemia treated initially with cladribine + prednisone or chlorambucil + prednisone in a randomized, cross-over study. We found higher complete and overall responses rates in patients who received cladribine + prednisone as first and second-line treatment but no significant differences in survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996945

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  3 in total

1.  Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

Authors:  Paula Cramer; Susanne Isfort; Jasmin Bahlo; Stephan Stilgenbauer; Hartmut Döhner; Manuela Bergmann; Martina Stauch; Michael Kneba; Elisabeth Lange; Petra Langerbeins; Natali Pflug; Gabor Kovacs; Valentin Goede; Anna-Maria Fink; Thomas Elter; Kirsten Fischer; Clemens-Martin Wendtner; Michael Hallek; Barbara Eichhorst
Journal:  Haematologica       Date:  2015-08-27       Impact factor: 9.941

Review 2.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Current and emerging treatments for chronic lymphocytic leukaemia.

Authors:  Tadeusz Robak; Krzysztof Jamroziak; Pawel Robak
Journal:  Drugs       Date:  2009       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.